Axe Compute Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $125.3K | $84.8K | $1.8M | $1.5M | $1.4M | $1.3M | $1.4M | $1.4M |
| Drug Discovery Services | $125.3K | $84.8K | $1.8M | $1.5M | — | — | — | — |
| Cost of Revenue | $72.6K | $78.3K | $609.2K | $505.1K | $487.0K | $447.2K | $531.8K | $415.8K |
| Gross Profit | $52.7K | $797.7K | $1.0M | $1.0M | $933.7K | $805.1K | $879.8K | $995.9K |
| Gross Margin | 42.0% | 940.5% | 57.2% | 66.4% | 65.7% | 64.3% | 62.3% | 70.5% |
| Operating Expenses | ||||||||
| Research & Development | — | $2.2M | $122.3K | $320.3K | $315.9K | $372.7K | $423.0K | $526.3K |
| SG&A Expense | $25.9M | $7.2M | $8.4M | $11.1M | $10.9M | $10.4M | $9.8M | $4.6M |
| Operating Income | $-180.9M | $-10.3M | $-12.1M | $-26.0M | $-20.4M | $-25.4M | $-22.6M | $-7.9M |
| Operating Margin | -144,404.5% | -12,149.1% | -680.7% | -1,729.3% | -1,437.9% | -2,025.1% | -1,604.2% | -556.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | $-25.7M | $-20.3M | $-25.9M | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $-661.7K | $0 | $0 | — |
| Net Income | $-233.1M | $-12.7M | $-14.0M | $-25.7M | $-19.7M | $-25.9M | $-19.4M | $-10.1M |
| Net Margin | -186,053.4% | -14,932.3% | -785.6% | -1,709.6% | -1,383.6% | -2,067.0% | -1,373.7% | -714.5% |
| EPS (Basic) | $-13.37 | $-34.83 | $-0.07 | $-0.15 | $-0.01 | $0.01 | $0.01 | $0.00 |
| EPS (Diluted) | — | — | — | — | $0.00 | $0.01 | $0.01 | $0.00 |
| Shares Outstanding (Basic) | 17.4M | 363.6K | 192.7M | 176.9M | 2.63B | 2.87B | 2.76B | 2.46B |
| Shares Outstanding (Diluted) | 17.4M | 363.6K | 192.7M | 176.9M | 2.63B | 2.87B | 2.76B | 2.46B |
| Dividends Per Share | — | — | — | — | — | — | — | — |